SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0001193125-22-292633
Filing Date
2022-11-25
Accepted
2022-11-25 16:25:29
Documents
1
Group Members
FRANK M. SANDS

Document Format Files

Seq Description Document Type Size
1 SC 13G d421450dsc13g.htm SC 13G 55843
  Complete submission text file 0001193125-22-292633.txt   57401
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Subject) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-93824 | Film No.: 221420415
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O SANDS CAPITAL VENTURES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209
Business Address C/O SANDS CAPITAL VENTURES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209 703-562-4000
Sands Capital Life Sciences Pulse Fund II, L.P. (Filed by) CIK: 0001875620 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9
Type: SC 13G